Skip to main content
 
 
 
MENU
VISIT JANSSEN GLOBAL

EMEA
change location▼

Search
Search
COVID-19 UPDATES >

VISIT JANSSEN GLOBAL

COVID-19 UPDATES >
Janssen EMEA › Media Center

Media Center

The Media Center is intended to provide resources for media professionals only. It is not intended for use by healthcare professionals, patients or the general public. To access, please confirm that you are an accredited member of the press. I hereby confirm that I am an accredited member of the press
I Agree
Cancel

Press Releases

May 26, 2022

European Commission Grants Conditional Approval of CARVYKTI® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

May 25, 2022

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA®▼ (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022

May 18, 2022

New Data Show TREMFYA®▼ (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab  

Apr 28, 2022

Janssen Submits Marketing Authorisation Application to EMA Seeking Approval of Niraparib and Abiraterone Acetate Dual Action Tablet Plus Prednisone for the Treatment of Patients with HRR Gene-Mutated Metastatic Castration Resistant Prostate Cancer

Mar 25, 2022

Janssen Receives Positive CHMP Opinion Recommending CARVYKTI® (Ciltacabtagene Autoleucel) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Mar 25, 2022

New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with TREMFYA®▼ (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatment History  

View more Press Releases

Media Backgrounders

Neuroscience Backgrounder

Schizophrenia Backgrounder

Waldenström’s Macroglobulinemia (WM)

The Role Of The Immune System In Crohn’s Disease

Stelara MOA infographic

About Crohn’s Disease Backgrounder

VIEW MORE MEDIA BACKGROUNDERS

VIRTUAL ONCOLOGY PRESSROOM

Quick Links

 

Tweets

 
Follow us on Twitter
SUBSCRIBE TO OUR YOUTUBE CHANNEL